AR123805A1 - Cápsulas blandas de liberación modificada - Google Patents

Cápsulas blandas de liberación modificada

Info

Publication number
AR123805A1
AR123805A1 ARP210102856A ARP210102856A AR123805A1 AR 123805 A1 AR123805 A1 AR 123805A1 AR P210102856 A ARP210102856 A AR P210102856A AR P210102856 A ARP210102856 A AR P210102856A AR 123805 A1 AR123805 A1 AR 123805A1
Authority
AR
Argentina
Prior art keywords
dependent
controlled release
modified release
tract
active agent
Prior art date
Application number
ARP210102856A
Other languages
English (en)
Spanish (es)
Inventor
Qi Fang
Karunakar Sukuru
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of AR123805A1 publication Critical patent/AR123805A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP210102856A 2020-10-16 2021-10-15 Cápsulas blandas de liberación modificada AR123805A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063092762P 2020-10-16 2020-10-16

Publications (1)

Publication Number Publication Date
AR123805A1 true AR123805A1 (es) 2023-01-11

Family

ID=81208677

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102856A AR123805A1 (es) 2020-10-16 2021-10-15 Cápsulas blandas de liberación modificada

Country Status (13)

Country Link
US (1) US20230390210A1 (cg-RX-API-DMAC10.html)
EP (1) EP4228597A4 (cg-RX-API-DMAC10.html)
JP (1) JP7897229B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230088388A (cg-RX-API-DMAC10.html)
CN (1) CN116322655A (cg-RX-API-DMAC10.html)
AR (1) AR123805A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021362248A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023006154A2 (cg-RX-API-DMAC10.html)
CA (1) CA3194160A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023005753A2 (cg-RX-API-DMAC10.html)
IL (1) IL301715A (cg-RX-API-DMAC10.html)
MX (1) MX2023004418A (cg-RX-API-DMAC10.html)
WO (1) WO2022082222A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117705978A (zh) * 2023-12-14 2024-03-15 河南泰丰生物科技有限公司 一种四烯甲奈醌软胶囊溶出曲线的测定方法
CN122458978A (zh) * 2023-12-22 2026-07-24 花王株式会社 胶囊剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61151127A (ja) * 1984-12-25 1986-07-09 Meiji Milk Prod Co Ltd ビフイズス菌含有ソフトカプセルの製造方法
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
DE60238269D1 (de) * 2001-11-22 2010-12-23 Morishita Jintan Co Nicht-gelatinöse Kapseln
KR100575199B1 (ko) * 2003-01-24 2006-05-02 알앤피코리아주식회사 연질 캡슐의 블루밍 방지를 위한 가소제 조성물 및 이를함유한 피막
IT1401313B1 (it) * 2010-08-05 2013-07-18 Perfetti Van Melle Spa Caramelle gelatinose con ripieno fluido e metodo di ottenimento
US20120301546A1 (en) * 2011-05-26 2012-11-29 Hassan Emadeldin M Acid-resistant soft gel compositions
GB201304662D0 (en) * 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
GB201319792D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015200149A1 (en) 2014-06-23 2015-12-30 Banner Life Sciences Llc All natural enteric soft capsules comprising active ingredients
US9877971B2 (en) * 2015-06-15 2018-01-30 Banner Life Sciences Llc Soft lozenges comprising corticosteroids
US20170119680A1 (en) * 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
AU2019362883B2 (en) * 2018-10-16 2025-07-31 Bayer Healthcare Llc Softgels with solid or gel-like polymeric fill matrix
EP4674410A3 (en) * 2019-10-28 2026-03-18 R.P. Scherer Technologies, LLC Delayed release softgel capsules in higher ph environment

Also Published As

Publication number Publication date
MX2023004418A (es) 2023-05-04
CO2023005753A2 (es) 2023-05-29
IL301715A (en) 2023-05-01
KR20230088388A (ko) 2023-06-19
TW202228656A (zh) 2022-08-01
JP7897229B2 (ja) 2026-07-29
CN116322655A (zh) 2023-06-23
WO2022082222A1 (en) 2022-04-21
JP2023547062A (ja) 2023-11-09
CA3194160A1 (en) 2022-04-21
BR112023006154A2 (pt) 2023-05-09
AU2021362248A9 (en) 2024-05-02
EP4228597A4 (en) 2024-10-02
US20230390210A1 (en) 2023-12-07
AU2021362248A1 (en) 2023-06-01
EP4228597A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
PE20180931A1 (es) Metodo de cristalizacion y biodisponibilidad
CO2023007156A2 (es) Cápsulas de gel blando de liberación retardada
CO6290641A2 (es) Preparacion de capsula que contiene los ingredientes farmaceuticamente activos liquidos y solidos, la cual presenta exelentes propiedades de los ingredientes farmaceuticamente activos
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
ECSP19082194A (es) Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
MX387217B (es) Composiciones de solución sólida para aines.
CY1117964T1 (el) Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας
MX2018003096A (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
CL2020002993A1 (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019)
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
CO2022019321A2 (es) Cápsulas de gel de liberación retardada
ES3063790T3 (en) Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CR20170142A (es) Composiciones farmacéuticas resistentes al abuso
CO2023005753A2 (es) Cápsulas de gelatina blanda de liberación modificada
MX2023005451A (es) Capsulas de gel blando de liberacion retardada.
PH12015000297B1 (en) Pharmaceutical combination preparation
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
BR112015022946A2 (pt) forma de dosagem de cápsula de gelatina macia farmacêutica com goma guar modificada
MX2018001989A (es) Formulaciones farmaceuticas.
MX2019004938A (es) Cápsula compleja que contiene esomeprazol y método de preparación de esta.
SV2006001916A (es) Formulaciones farmaceuticas transdermales
CL2021003286A1 (es) Cápsula de tipo desintegración retardada y método para producir la misma.
MX2021010959A (es) Estabilidad mejorada de ingredientes farmaceuticos activos (api) en capsulas blandas.
CL2019001555A1 (es) Preparación farmacéutica y método para su fabricación.
MX2018008153A (es) Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, metodo para prepararlos y composición farmacéutica que los contiene.